View Document Preview and Link Document Date: 2011-09-15 04:30:05 Open Document File Size: 29,88 KB Share Result on Facebook
City Tokyo / Lisbon / / Company Kotobuki Pharmaceutical Co. Ltd. / Astellas Pharma Inc. / / Event FDA Phase / / Facility Shiga University of Medical Science / / / MedicalCondition insulin resistance / diabetes mellitus / disorder / non-insulin-dependent diabetes mellitus / type 2 diabetes mellitus / deficiency / Diabetes / / Organization European Association for the Study of Diabetes / European Union / European Association for the Study of Diabetes Meeting TOKYO / Shiga University of Medical Science / / Person Atsunori Kashiwagi / / / Position Major / / Product ASP1941 / / Technology pharmacokinetics / pharmacodynamics / / URL http / SocialTag 
For Immediate Release Astellas Announces Oral Presentation of SGLT2 Inhibitor Detailing Safety and Efficacy in Patients with Type 2 Diabetes at the European Association for the Study of Diabetes Meeting TOKYO, September